Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF vs autologous bone marrow progenitor cells in idiopathic dilated cardiomyopathy
2009-013112-12Phase 2Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Mar 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of lenograstim in idiopathic dilated cardiomyopathy (IDC) and dilated cardiomyopathy (DCM) (2 arms), sponsored by Barts Health NHS Trust. Primary endpoint: Change in left ventricular ejection fraction at 3 months. Started Mar 2010; status: completed.
02
Drugs
lenograstim
03
Conditions
idiopathic dilated cardiomyopathy (IDC)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2009-013112-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013112-12.